AZ3 Inhibitors encompass a diverse array of chemical compounds, each with the potential to inhibit the functional activity of AZ3 through various biochemical pathways. Erlotinib and Sorafenib, for example, serve as tyrosine kinase inhibitors, potentially decreasing AZ3 activity if it is regulated by tyrosine kinase phosphorylation. Rapamycin, targeting mTOR signaling, might diminish AZ3's role in protein synthesis and proliferation if AZ3 is a participant in these pathways. In a similar vein, Triciribine and the PI3K inhibitors Wortmannin and LY 294002 could reduce AZ3 activity through the AKT pathway, illustrating the intricate web of cellular signaling in which AZ3 inhibitors operate. Additionally, U0126 and SB 203580, by inhibiting MEK and p38 MAPK respectively, could indirectly suppress AZ3 if it is intertwined with the MAPK/ERK or p38 MAPK pathways. Moreover, SP600125 and Dasatinib, which inhibit JNK and Src kinases, hint at the complex regulatory networks that AZ3 might be a part of, with their inhibition leading to a decrease in AZ3's activity.
Addressing other facets of the signaling milieu, Maraviroc, by blocking CCR5, suggests a potential interaction with AZ3 if it is part of the chemokine receptor'spathway. This targeted blockade would lead to a decrease in AZ3 signaling activity. ZM-447439's inhibition of Aurora kinase offers another route, where the functional activity of AZ3 could be diminished by the alteration of cell cycle-related processes if AZ3 operates within this context. The JNK pathway inhibitor SP600125 further exemplifies the precision of chemical interventions, potentially leading to decreased AZ3 activity through stress and inflammatory signaling pathways. The collective action of these inhibitors, targeting distinct kinases and signaling nodes, represents a concerted approach to diminishing the functional activity of AZ3 without affecting its expression levels. Each inhibitor, through its specific mechanism, contributes to the regulatory cascade that influences AZ3's role in cellular processes, thereby establishing a framework of potential inhibitory effects that are as diverse as they are specific to the biochemical underpinnings of AZ3's activity.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
As a tyrosine kinase inhibitor, Erlotinib could reduce the activity of kinases that phosphorylate AZ3, leading to a decrease in AZ3's functional activity if AZ3 is a substrate or is regulated by tyrosine kinase activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a kinase that can regulate protein synthesis and cell proliferation. If AZ3 is involved in these pathways, its functional activity would be diminished due to the downstream effects of mTOR inhibition. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases, potentially reducing the phosphorylation state of AZ3 or its associated signaling proteins, leading to a decrease in AZ3's functional activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine inhibits AKT, which may play a role in the regulation of AZ3, leading to decreased activity of AZ3 through reduced phosphorylation or activation of downstream targets. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
By inhibiting MEK, U0126 impairs the MAPK/ERK pathway, which could indirectly lead to a decrease in AZ3's activity if AZ3 is involved in or regulated by this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, potentially diminishing the PI3K/AKT signaling pathway which could regulate AZ3's activity, resulting in reduced functional activity of AZ3. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 inhibits PI3K, which could lead to decreased AZ3 activity if AZ3 is involved in the PI3K/AKT pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 inhibits p38 MAPK, potentially diminishing AZ3's activity if AZ3 is regulated by or involved in the p38 MAPK signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
As an inhibitor of JNK, SP600125 could decrease AZ3's activity if AZ3's function is modulated by the JNK signaling pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a Src kinase inhibitor, could decrease AZ3 functional activity if AZ3 is regulated by Src kinase activity or is part of a pathway involving Src kinases. | ||||||